M&A deals, company strategies, pipeline updates and more
Follow our coverage of the 2019 J.P. Morgan Healthcare Conference in San Francisco
Thanks to groundwork laid by the feds, UnitedHealthcare is suing dozens of generics companies for alleged price fixing—and it wants its money back.
Thanks to new guidance from England’s drug cost watchdog, Novartis and Roche will be getting some fresh targeted melanoma competition.
With new funding, ICER plans annual reviews for price hikes that aren't supported by new clinical evidence.
AbbVie and Johnson & Johnson’s blockbuster Imbruvica is approved to treat six diseases, but it looks like pancreatic cancer won’t be its seventh.
Emerging markets have been holding Takeda back, despite double-digit growth in China. Now, the company could reap some cash by selling some of those products.
The four-year GSK chairman joined the company when the drugmaker was reeling from bribery scandals and poor financial performance.
Should the FDA approve Sanofi’s SGLT2 candidate for patients with Type 1 diabetes? Turns out, the experts couldn't agree.
The new Senate is once again sharpening its ax to cut pharma's DTC advertising tax deductions, a move now backed by a powerhouse group of Democrats.
Terns names ex-Gilead executive as CMO; Spectrum sells all FDA-approved drugs to Aurobindo; Aslan's varlitinib fails in gastric cancer.
Lilly's Lartruvo has been a key launch for its oncology business, but thanks to a phase 3 fail, it plans to stop promoting the drug.
